Strategic Partnership with Roche
Zealand Pharma entered a transformative collaboration with Roche on petrelintide, which includes co-development and co-commercialization rights, and a 50/50 profit sharing in the US and Europe.
Strong Financial Position
Zealand Pharma has secured enough capital to fund its journey towards profitability, with cash, cash equivalents, and marketable securities totaling DKK 8.5 billion as of March 31, 2025.
Future Growth and Pipeline Expansion
The company plans significant new investments in its research pipeline targeting obesity and inflammation, supported by the Roche partnership.
Successful Enrollment in ZUPREME-1 Trial
Zealand Pharma completed enrollment for the Phase 2 ZUPREME-1 trial in March 2025, just three months after initiation.
Phase 3 Program for Survodutide
Boehringer Ingelheim completed enrollment in the Phase 3 synchronized cardiovascular outcomes trial for survodutide, which holds best-in-class potential for obesity and MASH treatment.